Matthias P Wymann

List of Publications by Year
in descending order

135 papers	14,933 citations	57 h-index (25034)	119 g-index (18647)
145 all docs	145 docs citations	145 times ranked	15417 citing authors

#	Article	IF	Citations
1	Central Role for G Protein-Coupled Phosphoinositide 3-Kinase Î³ in Inflammation. Science, 2000, 287, 1049-1053.	12.6	1,187
2	Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. Molecular Cell, 2000, 6, 909-919.	9.7	1,102
3	Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 2008, 9, 162-176.	37.0	1,091
4	Blockade of PI3KÎ³ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Medicine, 2005, 11, 936-943.	30.7	711
5	Structure and function of phosphoinositide 3-kinases. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1998, 1436, 127-150.	2.4	582
6	Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways. Cell, 2002, 110, 737-749.	28.9	545
7	Targeting phosphoinositide 3-kinaseâ€"Moving towards therapy. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 159-185.	2.3	491
8	PI3KÎ³ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects. Cell, 2004, 118, 375-387.	28.9	446
9	Phosphoinositide 3-kinase signalling â€" which way to target?. Trends in Pharmacological Sciences, 2003, 24, 366-376.	8.7	374
10	Activation of PI3-Kinase Is Required for AMPA Receptor Insertion during LTP of mEPSCs in Cultured Hippocampal Neurons. Neuron, 2003, 38, 611-624.	8.1	317
11	Phosphoinositide 3-Kinase Î³ Is an Essential Amplifier of Mast Cell Function. Immunity, 2002, 16, 441-451.	14.3	292
12	Bifurcation of Lipid and Protein Kinase Signals of PI3K to the Protein Kinases PKB and MAPK. , 1998, 282, 293-296.		288
13	Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood, 2005, 106, 1432-1440.	1.4	274
14	PI(3)KÎ³ has an important context-dependent role in neutrophil chemokinesis. Nature Cell Biology, 2007, 9, 86-91.	10.3	233
15	Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3â€kinaseâ€, Rhoâ€, and Racâ€dependent signaling pathways. FASEB Journal, 2000, 14, 2329-2338.	0.5	230
16	Phosphoinositide 3-Kinase p110Î² Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. Science Signaling, 2008, 1, ra3.	3.6	219
17	Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4960-4964.	7.1	201
18	Resistance to thromboembolism in PI3KÎ³â€deficient mice. FASEB Journal, 2001, 15, 2019-2021.	0.5	201

#	Article	IF	Citations
19	Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Current Opinion in Cell Biology, 2005, 17, 141-149.	5.4	198
20	Turning on the respiratory burst. Trends in Biochemical Sciences, 1990, 15, 69-72.	7.5	197
21	Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB. Science, 2002, 295, 2088-2091.	12.6	190
22	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110Î³. Molecular Cell, 2011, 42, 84-95.	9.7	174
23	The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression. Molecular and Cellular Biology, 2008, 28, 5886-5898.	2.3	150
24	Defective dendritic cell migration and activation of adaptive immunity in PI3KÎ³-deficient mice. EMBO Journal, 2004, 23, 3505-3515.	7.8	146
25	Chemiluminescence detection of H2O2 produced by human neutrophils during the respiratory burst. Analytical Biochemistry, 1987, 165, 371-378.	2.4	145
26	A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphateâ€"mediated egress. Journal of Experimental Medicine, 2007, 204, 497-510.	8.5	144
27	Cutting Edge: T Cell Development Requires the Combined Activities of the p110Î³ and p110Î´ Catalytic Isoforms of Phosphatidylinositol 3-Kinase. Journal of Immunology, 2005, 175, 2783-2787.	0.8	142
28	The<i>Drosophila</i>insulin/IGF receptor controls growth and size by modulating PtdIns<i>P</i>3 levels. Development (Cambridge), 2002, 129, 4103-4109.	2.5	142
29	Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-Î³ Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes. Circulation, 2008, 117, 1310-1317.	1.6	131
30	The Ras/Rac1/Cdc42/SEK/JNK/c-Jun Cascade Is a Key Pathway by Which Agonists Stimulate DNA Synthesis in Primary Cultures of Rat Hepatocytes. Molecular Biology of the Cell, 1998, 9, 561-573.	2.1	127
31	Phosphoinositide 3-kinase Î³: a key modulator in inflammation and allergy. Biochemical Society Transactions, 2003, 31, 275-280.	3.4	125
32	Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. Human Molecular Genetics, 2002, 11, 1569-1579.	2.9	124
33	Lipids on the move: phosphoinositide 3-kinases in leukocyte function. Trends in Immunology, 2000, 21, 260-264.	7.5	122
34	Inactivation of PI3KÎ³ and PI3KÎ´ distorts T-cell development and causes multiple organ inflammation. Blood, 2007, 110, 2940-2947.	1.4	113
35	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry, 2017, 60, 7524-7538.	6.4	109
36	Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils.. Journal of Clinical Investigation, 1991, 87, 2012-2017.	8.2	106

#	Article	IF	Citations
37	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Molecular Cancer Research, 2009, 7, 601-613.	3.4	105
38	Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO Journal, 2009, 28, 2018-2027.	7.8	103
39	Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase <i>Î³</i>: structureâ€“activity analysis and interactions with wortmannin. Biochemical Journal, 1997, 324, 489-495.	3.7	100
40	The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. FEBS Letters, 2004, 577, 539-544.	2.8	95
41	Requirement for PI 3-kinase Î³ in macrophage migration to MCP-1 and CSF-1. Experimental Cell Research, 2003, 290, 120-131.	2.6	94
42	A Selective Role for Phosphatidylinositol 3,4,5-Trisphosphate in the Gi-dependent Activation of Platelet Rap1B. Journal of Biological Chemistry, 2003, 278, 131-138.	3.4	92
43	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
44	Elastin-derived peptides potentiate atherosclerosis through the immune Neu1â€“PI3KÎ³ pathway. Cardiovascular Research, 2014, 102, 118-127.	3.8	91
45	Deconvolution of Buparlisibâ€™s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 2017, 8, 14683.	12.8	88
46	Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase Î± (PI3KÎ±). Journal of Biological Chemistry, 2001, 276, 21544-21554.	3.4	86
47	Phosphoinositide 3â€“kinase Î³ participates in T cell receptorâ€“induced T cell activation. Journal of Experimental Medicine, 2007, 204, 2977-2987.	8.5	86
48	Ras is an indispensable coregulator of the class I _B phosphoinositide 3-kinase p87/p110Î³. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20312-20317.	7.1	84
49	Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane. EMBO Journal, 2002, 21, 1673-1683.	7.8	80
50	PI3KÎ³ Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P ₃ Pools in Mast Cells. Science Signaling, 2009, 2, ra27.	3.6	80
51	Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio. Journal of Immunology, 2003, 170, 4475-4482.	0.8	79
52	Class IB-Phosphatidylinositol 3-Kinase (PI3K) Deficiency Ameliorates IA-PI3K-Induced Systemic Lupus but Not T Cell Invasion. Journal of Immunology, 2006, 176, 589-593.	0.8	78
53	The onset of the respiratory burst in human neutrophils. Real-time studies of H2O2 formation reveal a rapid agonist-induced transduction process. Journal of Biological Chemistry, 1987, 262, 12048-53.	3.4	76
54	Airway inflammation: chemokine-induced neutrophilia and the class?I phosphoinositide 3-kinases. European Journal of Immunology, 2005, 35, 1283-1291.	2.9	70

#	Article	IF	Citations
55	The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology, 2018, 140, 107-120.	4.1	64
56	Protein adsorption on topographically nanostructured titanium. Surface Science, 2001, 474, L180-L184.	1.9	62
57	Lack of phosphoinositide 3-kinase-Î³ attenuates ventilator-induced lung injury*. Critical Care Medicine, 2006, 34, 134-141.	0.9	62
58	PKCÎ² Phosphorylates PI3KÎ³ to Activate It and Release It from GPCR Control. PLoS Biology, 2013, 11, e1001587.	5.6	62
59	Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of Medicinal Chemistry, 2018, 61, 10084-10105.	6.4	62
60	Leukocyte transmigration is modulated by chemokineâ€mediated PI3KÎ³â€dependent phosphorylation of vimentin. European Journal of Immunology, 2009, 39, 1136-1146.	2.9	59
61	Essential Role of the p110Î² Subunit of Phosphoinositide 3-OH Kinase in Male Fertility. Molecular Biology of the Cell, 2010, 21, 704-711.	2.1	58
62	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase Î³. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14354-14359.	7.1	57
63	PI3KÎ³ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E854-63.	7.1	55
64	Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Postischemic Microvasculature. PLoS ONE, 2011, 6, e17229.	2.5	54
65	C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. Blood, 2012, 120, 880-890.	1.4	52
66	Cellâ€Permeant and Photocleavable Chemical Inducer of Dimerization. Angewandte Chemie - International Edition, 2014, 53, 4717-4720.	13.8	51
67	Human PI3KÎ³ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nature Communications, 2019, 10, 4364.	12.8	51
68	Respiratory burst oscillations in human neutrophils and their correlation with fluctuations in apparent cell shape. Journal of Biological Chemistry, 1989, 264, 15829-34.	3.4	51
69	Ablation of Phosphoinositide 3-Kinase-Î³ Reduces the Severity of Acute Pancreatitis. American Journal of Pathology, 2004, 165, 2003-2011.	3.8	49
70	Chemical Development of Intracellular Protein Heterodimerizers. Chemistry and Biology, 2013, 20, 549-557.	6.0	49
71	N-formyl peptide receptors in human neutrophils display distinct membrane distribution and lateral mobility when labeled with agonist and antagonist.. Journal of Cell Biology, 1993, 121, 1281-1289.	5.2	46
72	(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry, 2019, 62, 6241-6261.	6.4	45

#	Article	IF	Citations
73	GABAA receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABAA receptors. Neuropharmacology, 2007, 52, 146-155.	4.1	44
74	Increased breakdown of phosphatidylinositol 4,5-bisphosphate is not an initiating factor for actin assembly in human neutrophils. Journal of Biological Chemistry, 1988, 263, 17385-9.	3.4	44
75	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica, 2019, 104, e256-e259.	3.5	43
76	A class of highly selective inhibitors bind to an active state of PI3KÎ³. Nature Chemical Biology, 2019, 15, 348-357.	8.0	42
77	Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell Formation. PLoS ONE, 2013, 8, e58054.	2.5	42
78	Weakening link to colorectal cancer?. Nature, 2001, 413, 796-796.	27.8	41
79	Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3KÎ³-dependent fluid-phase pinocytosis of native LDL. Journal of Lipid Research, 2012, 53, 34-42.	4.2	39
80	The Chemical Biology of Phosphoinositide 3â€Kinases. ChemBioChem, 2012, 13, 2022-2035.	2.6	35
81	Essential role of phosphoinositide 3â€kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. Immunology, 2009, 126, 413-422.	4.4	33
82	Phosphoinositide 3-kinase Î³ mediates microglial phagocytosis via lipid kinase-independent control of cAMP. Neuroscience, 2013, 233, 44-53.	2.3	30
83	Key role of PI3KÎ³ in monocyte chemotactic proteinâ€1 â€mediated amplification of PDGFâ€induced aortic smooth muscle cell migration. British Journal of Pharmacology, 2012, 166, 1643-1653.	5.4	29
84	Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy. Journal of Allergy and Clinical Immunology, 2013, 132, 959-968.	2.9	29
85	PI3KÎ³ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. Science Signaling, 2017, 10, .	3.6	29
86	Targeting PI3KÎ³ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. Journal of Experimental Medicine, 2014, 211, 1779-1792.	8.5	28
87	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethylâ€"Pyrimidine Moiety. ACS Medicinal Chemistry Letters, 2019, 10, 1473-1479.	2.8	28
88	Disease-related mutations in PI3KÎ³ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. ELife, 2021, 10, .	6.0	28
89	Oscillatory motion in human neutrophils responding to chemotactic stimuli. Biochemical and Biophysical Research Communications, 1987, 147, 361-368.	2.1	27
90	Covalent Proximity Scanning of a Distal Cysteine to Target PI3KÎ±. Journal of the American Chemical Society, 2022, 144, 6326-6342.	13.7	27

#	Article	IF	Citations
91	Susi, a Negative Regulator of Drosophila PI3-Kinase. Developmental Cell, 2005, 8, 817-827.	7.0	24
92	A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 8609-8630.	6.4	24
93	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology, 2020, 180, 108297.	4.1	23
94	The role of PI3KÎ³ in the immune system: new insights and translational implications. Nature Reviews Immunology, 2022, 22, 687-700.	22.7	22
95	Inhibition of phosphoinositide 3â€kinase Î³ attenuates inflammation, obesity, and cardiovascular risk factors. Annals of the New York Academy of Sciences, 2013, 1280, 44-47.	3.8	21
96	Phosphoinositide 3-kinase Î³-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovascular Research, 2003, 60, 242-249.	3.8	20
97	Phosphoinositide 3-kinase Î³ controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Letters, 2005, 579, 133-140.	2.8	20
98	Microquantification of Cellular andin VitroF-Actin by Rhodamine Phalloidin Fluorescence Enhancement. Analytical Biochemistry, 1998, 264, 185-190.	2.4	19
99	Targeting PI3K in neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1881-1890.	2.5	19
100	PI3K p110Î³ Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions. PLoS ONE, 2013, 8, e72674.	2.5	17
101	4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-am (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of Medicinal Chemistry, 2020, 63, 13595-13617.	6.4	17
102	Analysis of the murine phosphoinositide 3-kinase Î³ gene. Gene, 2000, 256, 69-81.	2.2	16
103	Genetic ablation of PI3KÎ³ results in defective ILâ€17RA signalling in T lymphocytes and increased ILâ€17 levels. European Journal of Immunology, 2012, 42, 3394-3404.	2.9	14
104	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	3.7	14
105	Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. Neuropharmacology, 2020, 162, 107812.	4.1	12
106	Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem, 2021, 16, 2744-2759.	3.2	12
107	The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5â€²-p-fluorosulfonylbenzoyladenosine. International Journal of Biochemistry and Cell Biology, 2001, 33, 249-259.	2.8	11
108	PI3KÎ³ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibitionâ€"Moving Towards Cell Specific PI3K Targeting?. Frontiers in Immunology, 2020, 11, 585070.	4.8	10

#	Article	IF	Citations
109	PI3Ksâ€"Drug Targets in Inflammation and Cancer. Sub-Cellular Biochemistry, 2012, 58, 111-181.	2.4	9
110	Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. Organic Process Research and Development, 2019, 23, 2416-2424.	2.7	8
111	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted bloodâ€"brain barrier permeability. RSC Medicinal Chemistry, 2021, 12, 579-583.	3.9	6
112	Phosphoinositide 3â€kinase gamma; participates in T cell receptorâ€induced T cell activation.. FASEB Journal, 2008, 22, 1064.12.	0.5	4
113	Neutral not a loss: phosphoinositides beyond the head group. Nature Methods, 2011, 8, 219-220.	19.0	3
114	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. Cancer Research, 2015, 75, 2664-2664.	0.9	3
115	Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. Cancer Research, 2015, 75, 4514-4514.	0.9	3
116	Targeting Phosphoinositide 3-Kinase â€" Five Decades of Chemical Space Exploration. Chimia, 2021, 75, 1037.	0.6	3
117	Luminal decoration of blood vessels by activated perivasal mast cells in allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 510-520.	5.7	2
118	Suppression of caspase 8 activity by a coronin 1â€"PI3KÎ´ pathway promotes T cell survival independently of TCR and IL-7 signaling. Science Signaling, 2021, 14, eabj0057.	3.6	2
119	Phosphoinositide 3-kinase Î³ mediates Jun kinase activation via its lipid-kinase activity. Advances in Enzyme Regulation, 2004, 44, 299-308.	2.6	1
120	Membrane dynamics in physiology and disease. FEBS Journal, 2013, 280, 2729-2729.	4.7	1
121	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
122	Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition. , 2015, , .		1
123	Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. , 2017, , .		1
124	Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530. , 2017, , .		1
125	Phosphoinositide 3-kinase Signalling â€" no lipids. Biochemical Society Transactions, 1999, 27, A74-A74.	3.4	0
126	Mast cell degranulation requires activation of PI3K Î³ by PKC Î². Cytokine, 2009, 48, 41.	3.2	0

#	Article	IF	Citations
127	0377 : Phosphoinositide 3-kinase gamma: a potential clinical target in the prevention of vascular damages inuced by arterial injury. Archives of Cardiovascular Diseases Supplements, 2015, 7, 134.	0.0	0
128	Vascular Remodeling in Cardiovascular Disease231Absence of PI3Kg leads to increased reendothelialization in mice through modulation of IP-10 secretion.232DPP4 inhibition mediates vascular protection in acute and chronic vascular injury233Effects of transforming growth factor beta signalling on smooth muscle cell phenotype in the angiotensin II-induced abdominal aortic aneurysm model. Cardiovascular Research, 2016, 111, S44-S44.	3.8	0
129	Phosphoinositide 3â€“kinase Î³ participates in T cell receptorâ€“induced T cell activation. Journal of Cell Biology, 2007, 179, i9-i9.	5.2	0
130	Abstract 393A: Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620. , 2016, , .		0
131	Abstract 1364: Novel 4-(pyrimidin-2-yl)morpholines targeting the colchicine-binding site of tubulin. , 2016, , .		0
132	Abstract 1336: Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor. , 2016, , .		0
133	Abstract 153: Tricyclic fused pyrimidinopyrrolo-oxazines reveal conformational preferences of morpholine for PI3K hinge region binding. , 2017, , .		0
134	Central role for phosphoinositide-3-kinase gamma/delta dependent signalling in eosinophilic pulmonary inflammation driven by innate lymphoid cells. , 2017, , .		0
135	Abstract 665: Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex. , 2020, , .		0